{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:35:17Z","timestamp":1780338917920,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01HL150852"],"award-info":[{"award-number":["U01HL150852"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["HL125018"],"award-info":[{"award-number":["HL125018"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["CA267368"],"award-info":[{"award-number":["CA267368"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT9425-24-1-0508"],"award-info":[{"award-number":["HT9425-24-1-0508"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0364"],"award-info":[{"award-number":["HT9425-23-1-0364"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011132","name":"Rutgers The State University of New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI129594"],"award-info":[{"award-number":["AI129594"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI130197"],"award-info":[{"award-number":["AI130197"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI124769"],"award-info":[{"award-number":["AI124769"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.omton.2025.200957","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:28:07Z","timestamp":1740587287000},"page":"200957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors"],"prefix":"10.1016","volume":"33","author":[{"given":"Youssef","family":"Sabha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-chi","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve Elizabeth","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chung","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongren","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Hyeon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-8088","authenticated-orcid":false,"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.200957_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200957_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200957_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.200957_bib4","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200957_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.200957_bib6","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.200957_bib7","article-title":"Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.200957_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2025.200957_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T\u00a0cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200957_bib10","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T\u00a0cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200957_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11010-022-04568-0","article-title":"Challenges of chimeric antigen receptor-T\/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies","volume":"478","author":"Wang","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.omton.2025.200957_bib12","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200957_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.200957_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T\u00a0cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2025.200957_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200957_bib16","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200957_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T\u00a0cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omton.2025.200957_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.200957_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s13238-017-0415-5","article-title":"Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV","volume":"8","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"key":"10.1016\/j.omton.2025.200957_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-022-00364-6","article-title":"CAR-NK cells for cancer immunotherapy: from bench to bedside","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2025.200957_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.omtm.2020.06.014","article-title":"Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways","volume":"18","author":"Yang","year":"2020","journal-title":"Mol Ther-Meth Clin D"},{"key":"10.1016\/j.omton.2025.200957_bib22","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.200957_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101309","article-title":"Chimeric antigen receptor T\u00a0cells targeting CD147 for non-small cell lung cancer therapy","volume":"16","author":"Chen","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omton.2025.200957_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13578-022-00822-6","article-title":"Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection","volume":"12","author":"Badeti","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.omton.2025.200957_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep32804","article-title":"CD147\/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis","volume":"6","author":"Xin","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200957_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143534","article-title":"IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15\/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation","volume":"13","author":"Battram","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.200957_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.200957_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/ejh.14132","article-title":"Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia","volume":"112","author":"Gupta","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omton.2025.200957_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T\u00a0cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.200957_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/2326-6066.CIR-15-0118","article-title":"Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.200957_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116628","article-title":"CD19 chimeric antigen receptor T\u00a0cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity","volume":"475","author":"Kim","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.omton.2025.200957_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","article-title":"Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T\u00a0cell therapy: a systematic review and Meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2025.200957_bib33","first-page":"32","article-title":"CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias","volume":"3","author":"Taneja","year":"2022","journal-title":"EJH"},{"key":"10.1016\/j.omton.2025.200957_bib34","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212567","article-title":"Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges","volume":"8","author":"Makita","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.omton.2025.200957_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainres.2013.02.010","article-title":"Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia","volume":"1506","author":"Zhou","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.omton.2025.200957_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","article-title":"Astrocytes are active players in cerebral innate immunity","volume":"28","author":"Farina","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omton.2025.200957_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11481-020-09907-w","article-title":"The far-reaching HAND of cART: cART effects on astrocytes","volume":"16","author":"Gonzalez","year":"2021","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.omton.2025.200957_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cells11111723","article-title":"Different Methods for Evaluating Microglial Activation Using Anti-Ionized Calcium-Binding Adaptor Protein-1 Immunohistochemistry in the Cuprizone Model","volume":"11","author":"Wittekindt","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omton.2025.200957_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fncel.2014.00211","article-title":"Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease","volume":"8","author":"Cabezas","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.omton.2025.200957_bib40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","article-title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system","volume":"32","author":"Hol","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.omton.2025.200957_bib41","article-title":"A quantitative analysis of spontaneous alternation behaviors on a Y-maze reveals adverse effects of acute social isolation on spatial working memory","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.200957_bib42","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1038\/nprot.2013.155","article-title":"Object recognition test in mice","volume":"8","author":"Leger","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omton.2025.200957_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5019367","article-title":"CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis","volume":"2017","author":"Peng","year":"2017","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.omton.2025.200957_bib44","doi-asserted-by":"crossref","first-page":"17411","DOI":"10.3390\/ijms151017411","article-title":"The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature","volume":"15","author":"Xiong","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2025.200957_bib45","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jcyt.2020.11.004","article-title":"Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in\u00a0vivo","volume":"23","author":"Uong","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2025.200957_bib46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/s43018-024-00764-7","article-title":"Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome","volume":"5","author":"Vinnakota","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2025.200957_bib47","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.200957_bib48","article-title":"N-linked glycosylation at Asn152 on CD147 affects protein folding and stability: promoting tumour metastasis in hepatocellular carcinoma","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:02:32Z","timestamp":1750910552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2950329925000268"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.200957","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.200957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200957"}}